Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) Meeting Abstract
| Authors: | Dent, R.; Im, S. A.; Espie, M.; Blau, S.; Tan, A. R.; Isakoff, S. J.; Oliveira, M.; Saura, C.; Wongchenko, M.; Kapp, A. V.; Chan, W. Y.; Singel, S. M.; Maslyar, D. J.; Baselga, J.; Kim, S. B. |
| Abstract Title: | Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 36s |
| Language: | English |
| ACCESSION: | WOS:000442916001031 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.1008 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1008 -- Source: Wos |
